Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Entrada Therapeutics, Inc. (TRDA) closed the last trading session at $16.17, gaining 14.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 20.33 indicates a 25.7% upside potential. However, an impressive consensus price target is not the only factor that indicates a potential upside in TRDA. This view is strengthened by the agreement among analysts that the company will report bet ...